IRCT20170609034406N12 IRCT 2024-09-26 Tabriz University of Medical Sciences The effect of allopurinol in preventing liver fibrosis in non-alcoholic fatty liver disease The effect of allopurinol in preventing liver fibrosis in non-alcoholic fatty liver disease: A Randomized Placebo-Controlled Clinical Trial 2024-11-21 anticipated 154 Complete https://irct.ir/trial/79150 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Online randomization and permuted block randomization will be done, and in this way, random sequences with specific codes will be created, Blinding description: Due to the double-blind nature of this study, a person who has no role in the intervention and checking the entry and exit criteria will perform the randomization online and assign the patients to the groups based on the random sequence created. Another person, who has no role in the intervention and is unaware of the allocation of patients, will package the drugs based on the codes. This randomization and assignment of codes remains hidden from the researchers and participants until the statistical analysis is completed. 3 Liver fibrosis in non-alcoholic fatty liver disease. Intervention 1: Intervention group: (Allopurinol + standard non-alcoholic fatty liver treatment): 77 patients will be included in the study based on inclusion and exclusion criteria and will receive 300 mg allopurinol once a day for 12 weeks along with standard treatments. Intervention 2: Control group: (receive placebo + standard non-alcoholic fatty liver treatment): 77 patients will be included in the study based on the entry and exit criteria and will receive a placebo equal to 300 mg of allopurinol once a day for 12 weeks along with standard treatments. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information.